Solanezumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Solanezumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Discontinued
Highest phase
14
Registered trials
11
Result records
58
Matched deals
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether Solanezumab can convert its Monoclonal antibody profile and APP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Solanezumab (query alias: solanezumab) |
|---|---|
| Modality / target | Monoclonal antibody; APP; APP inhibitors |
| Highest global status | Discontinued |
| Originator | Eli Lilly & Co. |
| Active developers | Not disclosed |
The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT02760602 | Phase 3 | Terminated | 26 | Change From Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog14) Score |
| JPRN-jRCT2080223374 | Phase 3 | completed | Not disclosed | Not disclosed |
| NCT02614131 | Phase 1 | Terminated | 50 | Number of Participants With One or More Serious Adverse Event (SAE) Considered by the Investigator to be Related to Study Drug Administration |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease
Phase 3; n=216; evaluation: Positive. Reported fields: AUROC(Replacing MRI with tau PET) = 83.1 %
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Phase 2/3; n=not disclosed; evaluation: not stated. Reported fields: CSF sTREM2 level = 1.12 ng/mL ( 0.43)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Phase 3; n=1169; evaluation: not stated. Reported fields: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score(Least Squares Mean) = -1.13 score on a scale (Standard Error, 0.16); Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score(Least Squares Mean): LS Mean difference (Final Values) = -0.30(95% CI, -0.816 to 0.220), P-Value = 0.260; Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score(Least Squares Mean): LS Mean difference (Final Values) = -0.30(95% CI, -0.816 to 0.220), P-Value = 0.260
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Solanezumab addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 58 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: APP records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-05-26 | Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium | Approved | US$7,000.0M stated total |
| 2026-01-12 | Novartis Makes $1.5B+ Alzheimer’s Play With China’s SciNeuro | Preclinical | US$165.0M upfront; US$1,500.0M stated total |
| 2025-12-15 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. acquires Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. | Preclinical | US$200.5M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Anti-transferrin receptor antibodies and uses thereof cross reference to related applications”. The milestone feed surfaced a patent-application signal described as “Antibody drug conjugate and application thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
